Aptamer Conjugates With N-Heterocyclic Carbene Metal Complexes for Targeted Drug Delivery

ABSTRACT

An aptamer-N-heterocyclic-carbene metal complex conjugate (aptamer-NHCM conjugate) or an aptamer-bis-N-heterocyclic-carbene metal complex conjugate (aptamer-bis-NHCM conjugate) includes an aptamer coupled through a hydrolytically stable bond to an N-heterocyclic-carbene metal complex (NHCM) or a bis-N-heterocyclic-carbene metal complex (bis-NHCM). The aptamer-NHCM conjugate is prepared where the chosen aptamer displays selective binding to a cell specific receptor, such that the cytotoxic NHCM can be directed specifically to cells responsible for a target disease (e.g., a specific cancer type). A method of preparing the aptamer-N-heterocyclic-carbene metal complex conjugate involves installing a coupling group to an N-heterocyclic-carbene metal complex that can specifically bond with a functional group on an aptamer; the bond, covalent or non-covalent, is stable hydrolytically in the absence of an environment that promotes intentional cleavage of the bond.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of International patentapplication no. PCT/US2015/039014, filed Jul. 2, 2015, which claims thebenefit of U.S. Provisional Application Ser. No. 62/019,960, filed Jul.2, 2014, the disclosures of which are hereby incorporated by referencein its entireties, including all figures, tables and drawings.

The Sequence Listing for this application is labeled “Seq-List.txt”which was created on Dec. 28, 2016 and is 1 KB. The entire contents ofthe sequence listing are incorporated herein by reference in itsentirety.

BACKGROUND OF INVENTION

Malignant neoplasms accounted for approximately 7.6 million deathsworldwide in 2008, and as the population ages, that number projects to13.2 million by 2030. Patient responses to specific drugs vary widelyand it is unreasonable to expect current drug therapies to combat theexpected increase in cancer deaths. Personalized medicine through theuse of individualized biomarkers provides a potential means of combatingthis problem. The biomarkers, proteins expressed by the specific cancercell, even to the patient's particular cancer, are exploited to detectand deliver chemotherapeutics. Polyclonal and monoclonal antibodiesperform this task rather well, but drawbacks exist due to the complexityand expense of antibody production in addition to the difficulty ofconjugating the antibodies to active cytotoxic agents. Even ifindividual biomarkers can be exploited to deliver chemotherapeuticagents to the cancer cell, multiple drugs must be engineered to kill themany different varieties and patient-specific cancers.

A potential approach is to exploit cancer-specific biomarkers to delivera drug that is highly cytotoxic to all cells in all patients. Thus, onlyone highly cytotoxic drug must be synthesized, as long as it isspecifically delivered to the cancer cell and then excreted.Cell-specific aptamers with a high affinity for leukemia, liver,lymphoma, colon, and most recently breast cancer, are known. Aptamersare very attractive drug delivery agents because they have low molecularweights, are formed by a relatively easy and reproducible DNA synthesis,display high binding affinities and molecular specificities, are easymodified, have fast tissue penetration, have low toxicity, are tunablein binding affinity, and are easy stored. Presently a number ofdiagnostic kits and imaging reagents using aptamers are in production.

No single cytotoxic drug has been identified, although many metal ionsare highly cytotoxic to cancer. Hence, a metal ion is an obvious choicefor an all-inclusive drug candidate. Moreover, since 1935 gold complexeshave served as effective aurotherapeutic agents. Auranofin, used totreat rheumatoid arthritis, is also highly active against cervicalcarcinoma (HeLa) cells in vitro and effective against cis-platinresistant cancer cells. Numerous derivatives of gold complexesdemonstrate high activity. However, as with most heavy metals includingcis-platin, accumulation in the body causes significant negative sideeffects. One mode of accumulation is metal ion complex degradation,whereby a metal-aqua complex is formed and is difficult to excrete.Auranofin contains an Au—P(CH₂CH₃)₃ gold bonded ligand, which has lowstability. As a result, Auranofin accumulates in the body, which isdetrimental. In contrast, N-heterocyclic carbene gold (NHCAu) complexeshave the remarkable stability engendered by the Au-carbon bond. NHCAucomplexes are stable towards water, acidic solutions, and heat—importantqualities for a good drug candidate.

NHCAu complexes have a significant advantage because aquation anddeposition of Au ions in the body can be minimized. Because NHC ligandsare highly modular, the rapid and easy modification of steric andelectronic properties of the metal complexes can fine-tune to thecomplex's cytotoxicity. Examples of NHCAu complexes that show activityare those in FIG. 1, which exhibit IC50 values as low as 0.21 μM forbreast carcinoma (MDA MB231). For example, the chiral di-gold complex 5of FIG. 1 exhibits activity towards cervical carcinoma (HeLa) with anIC50=8.7 μM. Unfortunately, the NHCAu complexes are also toxic to normalhealthy cells, as in the case of 5 where an IC50=4.6 μM for healthyembryonic kidney cells (HEK) is observed.

Currently, cancer-specific aptamer-NHCAu conjugates or otheraptamer-N-heterocyclic carbene metal (NHCM) conjugates are unknown butthey have the potential to avoid toxicity to normal cells, while stillbeing highly effective for the destruction of cancer cells. Thus, toprevent heavy metal accumulation in the patient and the undesired sideeffects, aptamer-NHCM conjugates where the gold or alternative metal ionremains attached to the aptamer are desirable.

BRIEF SUMMARY

Embodiments of the invention are aptamer-N-heterocyclic-carbene metalcomplex conjugates (aptamer-NHCM conjugates) andaptamer-bis-N-heterocyclic-carbene metal complex conjugates(aptamer-bis-NHCM conjugates). This design couples an aptamer to one ormore N-heterocyclic-carbene metal complexes (NHCMs) and/or one or morebis-N-heterocyclic-carbene metal complexes (bis-NHCMs) throughhydrolytically stable bonds between the NHCM and the aptamer. The NHCMsor bis-NHCMs can be Au, Ag, Pt, Pd, Ru, Ni, or Cu complexes that includeat least one N-heterocyclic-carbene ligand of the structure:

wherein R-groups are independently H, C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl,C₂-C₁₈ alkynyl, C₆-C₁₄ aryl, C₇-C₁₈ arylalkyl, C₈-C₁₈ arylalkenyl,C₈-C₁₈ arylalkynyl, C₁-C₁₈ alkoxy, C₆-C₁₄ aryloxy, C₇-C₁₈ arylalkyloxy,C₂-C₁₈ alkenyloxy, C₂-C₁₈ alkynyloxy, C₈-C₁₈ arylalkenyloxy, C₈-C₃₀arylalkynyloxy, C₂-C₃₀ alkylester, C₇-C₁₅ arylester, C₈-C₃₀alkylarylester, C₃-C₁₈ alkenylester, C₃-C₁₈ alkynylester, C₃-C₁₈ di- orpoly-ether, C₃-C₁₈ di- or poly-etherester, C₃-C₁₈ di- or poly-ester,C₃-C₁₈ di- or poly-amine, C₄-C₁₈ di- or poly-ene and optionallysubstituted or multiply substituted with any of Cl, Br, I, F, OH, R′₂N,R′SO₂, R′SO, R′S, R′₃Si, R′O, NH₂, C(O)OH, N₃, C≡CH, vicinaldisubstituted with C(O)OC(O), a cyclic conjugated diene, any saltsderived therefrom or any condensation or addition derivative substituenttherefrom, wherein R′ can be C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl, C₂-C₁₈alkynyl, C₆-C₁₄ aryl, C₇-C₁₈ arylalkyl, C₈-C₁₈ arylalkenyl, C₈-C₁₈arylalkynyl, C₁-C₁₈ alkoxy, C₆-C₁₄ aryloxy, C₇-C₁₈ arylalkyloxy, C₂-C₁₈alkenyloxy, C₂-C₁₈ alkynyloxy, C₈-C₁₈ arylalkenyloxy, C₈-C₃₀arylalkynyloxy, C₂-C₃₀ alkylester, C₇-C₁₅ arylester, C₈-C₃₀alkylarylester, C₃-C₁₈ alkenylester, C₃-C₁₈ alkynylester, C₃-C₁₈ di- orpoly-ether, C₃-C₁₈ di- or poly-etherester, C₃-C₁₈ di- or poly-ester,C₃-C₁₈ di- or poly-amine, C₄-C₁₈ di- or poly-ene, wherein at least oneof the R groups of the N-heterocyclic-carbene comprises the condensationor addition derivative substituent comprising the coupling unit thatforms the stable bond between the N-heterocyclic-carbene metal complexand the aptamer, wherein the condensation or addition derivativesubstituent is derived from condensation or addition of a —NH₂ and—C(O)OH, —N₃, and —C≡CH; —NH₂ and vicinal disubstituted —C(O)OC(O)—, orhomocyclic or heterocyclic conjugated diene and —C≡CH or —HC≡CH₂. Theaptamer is chosen to bind to a cancer cell specific receptor, such as aG-protein coupled receptor, epidermal growth factor receptor, tyrosinekinase receptor mutation variant III, or protein tyrosine kinasereceptor 7. The coupling unit can include an amide —NHC(O)—, a1,4-substituted triazole —N₃C₂H—; an imide [—C(O)]₂N—, abicycle[2.2.1]heptane —C₇H₈—, a substituted bicycle[2.2.1]heptane, a7-oxabicyclo[2.2.1]heptane —C₆H₆O—, a substituted7-oxabicyclo[2.2.1]heptane, a 7-azabicyclo[2.2.1]heptane —C₆H₇N—, asubstituted 7-azabicyclo[2.2.1]heptane, or a succinimide thioether.

Additionally or alternatively, a bis-N-heterocyclic-carbene metalcomplex can be included such that a plurality of N-heterocyclic-carbeneligands complex one or more metals and are coupled to an aptamer.N-heterocyclic-carbene ligands can be coupled through a framework thatlimits the degree of conformational freedom and disposes the ligands ina favorable orientation to complex a single metal ion. The framework canbe, but is not necessarily, a portion of the coupling unit forattachment of the aptamer. In an embodiment of the invention, theframework and N-heterocyclic-carbenes can be atrans-9,10-dihydro-9,10-ethanoanthracene-11,12-di-N-heterocyclic-carbene.

An embodiment of the invention is the treatment of a disease byadministering the aptamer-NHCM conjugate in a pharmaceutically effectiveamount to a patient with a cancer or a microbial infection. Theaptamer-NHCM conjugate binds to the disease causing cells via thespecific cell surface receptor present on the disease causing cells.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows exemplary NHCAu complexes that exhibit cytotoxicity at themicromolar level.

FIG. 2 shows reaction schemes to produce a carboxylic acid containingNHC-gold complex capable of conjugating to an aptamer, according to anembodiment of the invention.

FIG. 3 shows a reaction scheme to generate a silver salt from acarboxylate alkyl substituted imidazole zwitterion and converting theNHCAg complex into the NHCAu complex prior to conjugation with anaptamer, according to an embodiment of the invention.

FIG. 4 shows a reaction scheme to couple the carboxylic acid containingNHC-gold complex of FIG. 2 with the coupling reagents1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) andthe conjugation with an amine functionalized aptamer, according to anembodiment of the invention.

FIG. 5 shows a reaction scheme where a1-dimethylaminonaphthalene-5-sulfonamidopolymixin (dansp) flourophorefunctionalized NHC-gold complex is conjugated to an amine functionalizedaptamer, according to an embodiment of the invention.

FIG. 6 shows a reaction scheme for the preparation of the imidazoliumchloride salt 10 via alkylation with benzyl chloroacetate.

FIG. 7 shows a reaction scheme for generation of a benzyl protectedsilver(I) complex 11 followed by transmetalation with (CH₃)₂SAuCl toyield the benzyl ester protected monocarbene gold(I)-NHC complex 12,according to an embodiment of the invention.

FIG. 8 shows a reaction scheme to form alkyne functionalizedheterocycles 13-15.

FIG. 9 shows a reaction scheme for the deprotonation and metalation ofligand 13 with silver(I)oxide to form silver complex 16.

FIG. 10 shows composite ¹H-NMR spectra of the reaction of FIG. 9 overtime.

FIG. 11 shows a reaction scheme for the transmetalation of complex 16 togold(I) complex 17.

FIG. 12 shows a reaction scheme for the generation of a ligand conjugate28 and an NHC-gold conjugate 21, according to an embodiment of theinvention.

FIG. 13A is a plot of cell viability in the presence of 21aptamer-NHC-gold conjugate and FIG. 13B in the presence of 28.

FIG. 14 is a reaction scheme for the preparation of 27, a fluorescentdrug bound NHC-gold complex for conjugation with an amine functionalizedaptamer, according to an embodiment of the invention.

FIG. 15 is an emission spectrum of compound 27 under excitation at 389nm.

FIG. 16 is an emission spectra of FITC in water under excitation at 389nm.

FIG. 17 is a reaction scheme for conjugation of a fluorescent dye boundNHC-gold complex with an amine functionalized sgc8-aptamer or AS1411,according to an embodiment of the invention.

FIG. 18 is an emission spectra of the conjugate between fluorescent dyebound NHC-gold complex with an amine functionalized sgc8-aptamer,according to an embodiment of the invention as isolated by HPLC.

FIG. 19A shows a plot of MTS assays of complex 27 with CCRF-CEM cellline. IC₅₀=31.1±2.11 μM.

FIG. 19B shows a plot of MTS assays of conjugate 30 (sgc8c-27) withCCRF-CEM cell line. IC₅₀=2.39±1.50 μM.

FIG. 19C shows a plot of MTS assays of complex 27 with K562 cell line.

FIG. 20 shows a bar chart for comparison of the cytotoxicity betweenNHC—Au complexes 19 and 27 and their corresponding conjugates 21(sgc8c-19) and 30 (sgc8c-27).

FIG. 21 is a reaction scheme for the preparation of 29, a fluorescentdrug bound NHC-gold complex for conjugation with an amine functionalizedaptamer, from 27 according to an embodiment of the invention.

FIG. 22 shows a composite plot of MTS cell proliferation assays thatdemonstrate the specific cytotoxicity of complex 27 and its conjugate30sgc8c-27, according to an embodiment of the invention, towardsCCRF-CEM cells CCRF-CEM and K562 cells.

FIG. 23 is a table of MTS cell proliferation assay results of cancercell lines and normal cell lines after treated with cationic NHC—Aucomplex 29 and 32 (AS1411-29) conjugate, where AS1411 aptamer was usedas a control.

FIG. 24A shows a bar chart that compares the cell viability ofMDA-MB-231, HU1545 and HEK293 after incubation with NHC—Au complex 29.

FIG. 24B shows a bar chart that compares the cell viability ofMDA-MB-231, HU1545 and HEK293 after incubation with conjugate 32(AS1411-29).

FIG. 25A is a plot of the cell viability vs concentration for the MTSassay of complex 29 with MDA-MB-231 cell line. IC₅₀=21.1±1.06 μM.

FIG. 25B is a plot of the cell viability vs concentration for the MTSassay of complex 29 with DU145 cell line. IC₅₀=21.1±1.06 μM.

FIG. 25C is a plot of the cell viability vs concentration for the MTSassay of complex 29 with HEK293 cell line. IC₅₀=38.7±1.18 μM.

FIG. 25D is a plot of the cell viability vs concentration for the MTSassay of complex 29 with Hela cell line. IC₅₀=18.8±0.77 μM.

FIG. 25E is a plot of the cell viability vs concentration for the MTSassay of complex 29 with HU1545v cell line. IC₅₀=22.3±1.41 μM.

FIG. 25F is a plot of the cell viability vs concentration for the MTSassay of conjugate 32 (AS1411-29) with MDA-MB-231 cell line.IC₅₀=3.77±0.81 μM.

FIG. 25G is a plot of the cell viability vs concentration for the MTSassay of 32 (AS1411-29) with DU145 cell line. IC₅₀=3.92±0.70 μM.

FIG. 25H is a plot of the cell viability vs concentration for the MTSassay of 32 (AS1411-29) with Hela cell line. IC₅₀=2.04±0.16 μM.

FIG. 26A shows plots of normalized counts vs. FITC intensities for flowcytometry assays of conjugate 30 (sgc8c-27) with the K562 cell line.

FIG. 26B shows plots of normalized counts vs. FITC intensities for flowcytometry assays of conjugate 30 (sgc8c-27) with the CCRF-CEM cell line.

FIG. 27A shows plots of normalized counts vs. FITC intensities for flowcytometry analysis of MDA-MB-231 cells after incubation with 32(AS1411-29).

FIG. 27B shows plots of normalized counts vs. FITC intensities for flowcytometry analysis of PC3 cells after incubation with 32 (AS1411-29).

FIG. 27C shows plots of normalized counts vs. FITC intensities for flowcytometry analysis of HEK293 cells after incubation with 32 (AS1411-29).

FIG. 27D shows plots of normalized counts vs. FITC intensities for flowcytometry analysis of HU1545 cell after incubation with 32 (AS1411-29).

FIG. 28A shows a confocal microscopy image of CEM cells incubated with30 (sgc8c-27) labelled with fluorescein.

FIG. 28B shows a confocal microscopy image of CEM cells incubated withLIB-27 labelled with fluorescein.

FIG. 28C shows a confocal microscopy image of K562 cells incubated with30 (sgc8c-27) labelled with fluorescein.

FIG. 28D shows a confocal microscopy image of K562 cells incubated withLIB-27 labelled with fluorescein.

FIG. 29A shows a confocal microscopy images of HeLa cells treated with32 (AS1411-29) labelled with fluorescein.

FIG. 29B shows a confocal microscopy images of HU1545 cells treated with32 (AS1411-29) labelled with fluorescein.

BRIEF DESCRIPTION OF THE SEQUENCES

SEQ ID NO: 1: Sequence of sgc8c, an example of an aptamer.

SEQ ID NO: 2: Sequence of AS1411, an example of an aptamer

DETAILED DISCLOSURE

Embodiments of the invention are aptamer-N-heterocyclic-carbene metalcomplex conjugates (aptamer-NHCM conjugates) oraptamer-bis-N-heterocyclic-carbene metal complex conjugates(aptamer-bis-NHCM conjugates). These includeaptamer-N-heterocyclic-carbene gold complex conjugates (aptamer-NHCAuconjugates) or other aptamer-NHCM metal complex conjugates, fortargeting cancer cells. The aptamer-NHCM conjugates are constructed toensure that the gold or alternative metal ion complex remains intact andbound to the aptamer. In this manner, the decomposition of the metalcomplex is avoided along with heavy metal accumulation side effects. Theconjugation of the gold, or other metal ion complex, to the aptamer isthrough an inert and highly stable bond (e.g., an amide bond). Anembodiment of the invention involves a method to couple an aptamercontaining or adapted to contain a functionality that can bond with aNHCM complex containing the complementary functionality. In oneembodiment of the invention, the aptamer functionality is an amine andthe complementary functionality of the NHCM complex is a carboxylicacid. In another embodiment of the invention, the NHCM complex has aminefunctionality and an aptamer has a carboxylic acid couplingfunctionality. In other embodiments of the invention, the aptamer ismodified to attach a complementary functionality onto the aptamer andthe NHCM complex is equipped with a complementary functionality for theformation of at least one bond by a “click” reaction or other highconversion addition or condensation reactions. For example, thefunctionalities can be —N₃ and —C≡CH for a Huisgen cycloaddition, an-ene or an -yne, a conjugated diene, a cyclic diene or a heterocyclicdiene for a Diels-Alder cycloaddition, a primary amine and adicarboxylic acid anhydride for an imidization, a maleimide and a thiolfor a succinimide thioether, or any other complementary reactivefunctionalities for a high yield, stoichiometric reaction to couple theunits upon combining the aptamer and NHCM or bis-NHCM.

FIG. 2 shows two alternative reactions sequences to synthesize anexemplary carboxylic acid containing NHC-gold complex where an alkylimidazole reacts with a chloro substituted ester to yield an imidazoliumsalt in high yield. Subsequently, metalation followed or preceded byester hydrolysis forms the NHCAu complex with a carboxylic acid group.Other N-heterocyclic carbenes can be substituted for the exemplaryimidazole containing carbene Au complex, shown for an exemplary NHCAucomplex in FIG. 2, or used to prepare any alternative NHC-metal (NHCM)complex and ultimately the aptamer-NHCM conjugates. The carbene can beof the structure:

where R-groups are independently H, C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl, C₂-C₁₈alkynyl, C₆-C₁₄ aryl, C₇-C₁₈ arylalkyl, C₈-C₁₈ arylalkenyl, C₈-C₁₈arylalkynyl, C₁-C₁₈ alkoxy, C₆-C₁₄ aryloxy, C₇-C₁₈ arylalkyloxy, C₂-C₁₈alkenyloxy, C₂-C₁₈ alkynyloxy, C₈-C₁₈ arylalkenyloxy, C₈-C₃₀arylalkynyloxy, C₂-C₃₀ alkylester, C₇-C₁₅ arylester, C₈-C₃₀alkylarylester, C₃-C₁₈ alkenylester, C₃-C₁₈ alkynylester, C₃-C₁₈ di- orpoly-ether, C₃-C₁₈ di- or poly-etherester, C₃-C₁₈ di- or poly-ester,C₃-C₁₈ di- or poly-amine, C₄-C₁₈ di- or poly-ene and optionallysubstituted or multiply substituted with any of Cl, Br, I, F, OH, R′₂N,R′SO₂, R′SO, R′S, R′₃Si, R′O, NH₂, C(O)OH, N₃, C≡CH, vicinaldisubstituted with C(O)OC(O), a cyclic conjugated diene, or any saltsderived therefrom, wherein R′ can be C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl,C₂-C₁₈ alkynyl, C₆-C₁₄ aryl, C₇-C₁₈ arylalkyl, C₈-C₁₈ arylalkenyl,C₈-C₁₈ arylalkynyl, C₁-C₁₈ alkoxy, C₆-C₁₄ aryloxy, C₇-C₁₈ arylalkyloxy,C₂-C₁₈ alkenyloxy, C₂-C₁₈ alkynyloxy, C₈-C₁₈ arylalkenyloxy, C₈-C₃₀arylalkynyloxy, C₂-C₃₀ alkylester, C₇-C₁₅ arylester, C₈-C₃₀alkylarylester, C₃-C₁₈ alkenylester, C₃-C₁₈ alkynylester, C₃-C₁₈ di- orpoly-ether, C₃-C₁₈ di- or poly-etherester, C₃-C₁₈ di- or poly-ester,C₃-C₁₈ di- or poly-amine, C₄-C₁₈ di- or poly-ene, where, optionally, oneof the R groups of one of the N-heterocyclic-carbenes contains therequisite coupling functional group to a complementary functionalitynecessary for covalent attachment to the aptamer, where the couplingfunctional group is —NH₂, —C(O)OH, —N₃, —C≡CH; vicinal disubstituted—C(O)OC(O)—, or homocyclic or heterocyclic conjugated diene, where R andR′ groups are linear, branched, cyclic, polycyclic or any combinationthereof, and where the N-heterocyclic-carbene is achiral, racemicmixture, partially resolved enantiomer, resolved enantiomer, or amixture of diastereomers.

In an embodiment of the invention, the N-heterocyclic-carbene metalcomplex is a bis-N-heterocyclic-carbene metal complex, where a pluralityof N-heterocyclic-carbene ligands and one or more metals are coupled toan aptamer. In an embodiment of the invention, N-heterocyclic-carbeneligands can be positionally fixed through a framework that limits thedegree of conformational freedom to dispose the carbene ligands in afavorable orientation and proximity relative to each other to ligate asingle metal ion. The framework can be, but is not necessarily, aportion of the coupling unit. In an embodiment of the invention, theframework and N-heterocyclic-carbenes can be atrans-9,10-dihydro-9,10-ethanoanthracene-11,12-di-oligomethylene-N-heterocyclic-carbene:

where NHC indicates any of the NHC carbenes above, independently chosen,where one of the nitrogens of each of the two NHCs is bound to theterminal methylene of the oligomethylene links of the bicyclo framework,and where n is 1 to 4. For purposes of the invention, the oligomethylenecan be of a single methylene unit and does not require a plurality ofmethylene units to fulfill the definition of an oligomethylene. The Rgroups of the framework are independently defined as the R groups of theNHC carbenes, above. Thetrans-9,10-dihydro-9,10-ethanoanthracene-11,12-di-oligomethylene-N-heterocyclic-carbenecan be a symmetric bis-NHC, such as:

or an asymmetric bis-NHC, such as:

The bis-NHC metal complex, can have the structure:

wherein n and R are defined as above, R″ is independently:

wherein anion Z is Cl⁻, Br⁻, I⁻, BF₄ ⁻, PF₆ ⁻, SbF₆ ⁻, ⁻OSO₂CF₃, or⁻OSO₂C₆H₅, wherein M is Au, Ag, Rh, Ir, Pd, Pt, Ru, Ni, Cu, or othertransition metal, m is 0 to 3, and wherein R′″ is an optional ancillarybidentate diene ligand selected from the group consisting of norbornene,substituted norbornene, 1,5-cyclooctadiene, or substituted1,5-cyclooctadiene.

Although FIG. 2 shows an ethyl ester of the carboxylic acid, in otherembodiments of the invention, alternative esters can be used,particularly those whose conversion to the carboxylic acid is carriedout under mild conditions. These include, but are not limited to, benzyland silyl esters such as trimethylsilyl, triethylsilyl, ort-butyldimethylsilyl esters, which are liberated by hydrolysis orfluoride substitution, esters of fluorinated phenols, for examplepentafluorophenoxy esters, as well as alkyl esters prone to eliminationby ester pyrolysis. Other embodiments of the invention can employ aprecursor other than an ester that yield a carboxylic acid, for example,but not limited to, a mixed carboxylic acid anhydride, a carboxylic acidhalide, or other functionality that can be hydrolyzed to form acarboxylic acid. Additional embodiments of the invention include otherfunctionalities than those of a carboxylic acid derivative for formationof the carboxylic acid. These include, but not limited to, a nitrile,which can be hydrolyzed, or an aldehyde or alcohol which can be oxidizedto form the carboxylic acid. In another embodiment of the invention, thecarboxylic acid, or its carboxylate salt, can be used directly in thesynthesis of the NHCAu complex without an intermediate ester or othercarboxylic acid precursor functionality.

In addition to the route towards the NHCAu complex shown in FIG. 2,several alternative approaches to the synthesis of a carboxylic acidappended NHCAu complex can be carried out, including: cleavage of a C═Cbond in electron rich alkenes as disclosed in Ozdemir et al., AppliedOrganometallic Chemistry 2004, 18 (7), 318-322; generation of a freecarbene by deprotonation of the imidazolium precursor with a strong baseas disclosed in Bohler et al., New Journal of Chemistry 2002, 26 (10),1291-1295; transmetalation of a deprotonated azole followed byprotonation or alkylation of the gold azolyl compound as disclosed inRaubenheimer et al., Journal of Organometallic Chemistry 2001, 617 (1),170-181; in situ deprotonation of an imidazolium salt with a weak baseas disclosed in Poyatos et al., Inorganic Chemistry 2003, 42 (8),2572-2576; and transmetalation from a silver-NHC complex prepared by areaction of an imidazolium precursor with Ag₂O as disclosed in Wang etal., Organometallics 1998, 17 (5), 972-975 and Ozdemir et al., Molecules2010, 15 (4), 2203-2210, all of these references are incorporated hereinby reference.

Of these routes, a gold(I)-NHC complex is readily synthesized viatransmetalation from a corresponding silver(I)-NHC complex orbis-NHC-silver(I) halide salt by treatment with an appropriate gold(I)source. Carboxylate functionalized silver(I)-NHC complexes can bereadily prepared by the method disclosed in Moore et al.,Organometallics 2006, 25 (21), 5151-5158, which is incorporated herein.FIG. 3 shows a reaction scheme to generate a silver salt from acarboxylic acid alkyl substituted imidazole zwitterion and subsequentlyconvert the NHCAg complex to the NHCAu complex.

An NHCAu complex can comprise any of the structures:

and a bis-NHCAu complex can comprise any of the structures:

wherein X is Cl, Br, I or OH, Z is Cl⁻, Br⁻, I⁻, BF₄ ⁻, PF₆ ⁻, SbF₆ ⁻,⁻OSO₂CF₃, or ⁻OSO₂C₆H₅, and, independently, R-groups are independentlyH, C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl, C₂-C₁₈ alkynyl, C₆-C₁₄ aryl, C₇-C₁₈arylalkyl, C₈-C₁₈ arylalkenyl, C₈-C₁₈ arylalkynyl, C₁-C₁₈ alkoxy, C₆-C₁₄aryloxy, C₇-C₁₈ arylalkyloxy, C₂-C₁₈ alkenyloxy, C₂-C₁₈ alkynyloxy,C₈-C₁₈ arylalkenyloxy, C₈-C₃₀ arylalkynyloxy, C₂-C₃₀ alkylester, C₇-C₁₅arylester, C₈-C₃₀ alkylarylester, C₃-C₁₈ alkenylester, C₃-C₁₈alkynylester, C₃-C₁₈ di- or poly-ether, C₃-C₁₈ di- or poly-etherester,C₃-C₁₈ di- or poly-ester, C₃-C₁₈ di- or poly-amine, C₄-C₁₈ di- orpoly-ene and optionally substituted or multiply substituted with any ofCl, Br, I, F, OH, R′₂N, R′SO₂, R′SO, R′S, R′₃Si, R′O, NH₂, C(O)OH, N₃,C≡CH, vicinal disubstituted with C(O)OC(O), a cyclic conjugated diene,any salts derived therefrom or any condensation or addition derivativesubstituent therefrom, wherein R′ can be C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl,C₂-C₁₈ alkynyl, C₆-C₁₄ aryl, C₇-C₁₈ arylalkyl, C₈-C₁₈ arylalkenyl,C₈-C₁₈ arylalkynyl, C₁-C₁₈ alkoxy, C₆-C₁₄ aryloxy, C₇-C₁₈ arylalkyloxy,C₂-C₁₈ alkenyloxy, C₂-C₁₈ alkynyloxy, C₈-C₁₈ arylalkenyloxy, C₈-C₃₀arylalkynyloxy, C₂-C₃₀ alkylester, C₇-C₁₅ arylester, C₈-C₃₀alkylarylester, C₃-C₁₈ alkenylester, C₃-C₁₈ alkynylester, C₃-C₁₈ di- orpoly-ether, C₃-C₁₈ di- or poly-etherester, C₃-C₁₈ di- or poly-ester,C₃-C₁₈ di- or poly-amine, C₄-C₁₈ di- or poly-ene, wherein at least oneof the R groups of the N-heterocyclic-carbene comprises the condensationor addition derivative substituent that comprises the coupling unit withthe stable bond between the N-heterocyclic-carbene metal complex and theaptamer, where the condensation or addition derivative substituent isderived from condensation or addition of a —NH₂ and —C(O)OH, —N₃ and—C≡CH; —NH₂ and vicinal disubstituted —C(O)OC(O)—, homocyclic orheterocyclic conjugated diene and —C≡CH or —HC═CH₂, or —SH and amaleimide, wherein R and R′ groups are linear, branched, cyclic,polycyclic or any combination thereof, and wherein theN-heterocyclic-carbene is achiral, a racemic mixture, partially resolvedenantiomer, resolved enantiomer, resolved diastereomers, or a mixture ofdiastereomers. The undefined bonding to a nitrogen of the N-heterocycliccarbene can be to an R group or can be attached to a framework, such asto the terminal position of the oligomethylenetrans-9,10-dihydro-9,10-ethanoanthracene-11,12-di-oligomethylene-N-heterocyclic-carbene.

In other embodiments of the invention, the Au metal can be substitutedby Ag, Pt, Pd, Ru, Ni, or Cu, where the additional X, Z⁻, and/or NHCligands lacking a site for coupling with an aptamer can be included inthe complex as required by the oxidation state of the metal ion in thecomplex, as the metal ion can be in any oxidation state.

Aptamers are polynucleotide or polypeptide molecules that bind to aspecific target molecule. Non-limiting examples of aptamers include: DNAaptamers; RNA aptamers; XNA (nucleic acid analogs or artificial nucleicacids) aptamers; and polypeptide aptamers. Examples of XNA include, butare not limited to, polypeptide nucleic acid (PNA), morpholino andlocked nucleic acid (LNA), glycol nucleic acid (GNA), and threosenucleic acid (TNA).

NHCM can be conjugated to aptamers in a covalent or a non-covalentmanner. NHCM can be covalently conjugated to aptamers directly or viamolecular linkers. Various molecular linkers are known to a person ofordinary skill in the art, and certain non-limiting examples aredescribed in “Easy molecular bonding crosslinking technology” publishedby Thermo Scientific (2012), the contents of which are hereinincorporated by reference in its entirety.

In an embodiment of the invention, the covalent bond between the aptamerand NHCM is acid labile so that the covalent bond is broken between theNHCM and the conjugated aptamer as the NHCM and aptamer are internalizedby the target cells and subjected to the acidic environment of theendosomes, thereby releasing the NHCMs into the target cells. An exampleof acid labile cross-linking involves the use ofN-(Epsilon-Maleimidocaproic Acid) hydrazide to conjugate NHCM withaptamers. Additional examples of acid labile covalent binding are knownto a person of ordinary skill in the art and such embodiments are withinthe purview of the current invention.

In another embodiment of the invention, the NHCM is conjugated to theaptamer in a non-covalent manner. Non-limiting examples of non-covalentbinding between NHCM and aptamers include electrostatic binding,xi-binding, van der Waals interactions, and hydrophobic binding betweenthe NHCM and the aptamers.

Aptamer conjugated NHCM complexes can be used to specifically deliverthe NHCM complexes to target cells, e.g., cancer cells. The aptamers canselectively recognize target cells through specific cell surfaceproteins, and direct the tethered NHCM complexes to the target cells.NHCM complexes specifically targeted and delivered to target cells cankill the target cells (e.g., cancer cells), without affecting thenon-targeted cells (e.g., normal cells). As such, the current inventionprovides compositions and methods for treating a disease, e.g., cancer,in a subject. The aptamer is capable of binding to a cell surfacereceptor present on a target cell. The cell surface receptor can bespecific to the target cells, i.e., the cell surface receptor is presentonly on the surfaces of target cells and is absent from the surfaces ofnon-target cells, or the surface receptor is present on the surfaces oftarget cells at a high level and is present on the surfaces ofnon-target cells at a significantly lower level than that of the targetcells. For example, the aptamer can bind to a cell surface receptorspecific to cancer cells, i.e., a cell surface receptor which is presentonly on the surfaces of cancer cells and is absent from the surfaces ofnormal cells or is present on the surfaces of cancer cells at high leveland is present on the surfaces of normal cells at a significantly lowerlevel. The aptamer can bind to a cell surface receptor specific to aninfectious agent, i.e., a cell surface receptor which is present only onthe surfaces of infectious agents and is absent from the surfaces ofnormal cells or is present on the surfaces of infectious agents at highlevel and is present on the surfaces of normal cells at a significantlylower level.

Accordingly, the diseases that can be treated, according to compositionsand methods of the invention, include cancer, microbial infections andother diseases where the disease causing cells exhibit presence of aspecific cell surface receptor that can be exploited to target thediseased cells. Various cancers that can be treated, according to anembodiment of the invention, are well known to a person of ordinaryskill in the art and such cancers are within the purview of the currentinvention. The microbial infections can be viral, fungal, bacterial,protozoan, or prion mediated.

To treat a disease, according to an embodiment of the invention, anaptamer can be selected for its capability to bind to all or most of thetarget cells in a subject without binding to all or most of thenon-target cells. An aptamer can bind to a target cell through a targetcell specific receptor. For example, to treat cancer according to anembodiment of the invention, the aptamer can be selected for its abilityto bind to most or all of the cancer cells without binding to all ormost of the normal cells through a receptor specific for cancer cells.Non-limiting examples of cancer cell specific receptors include,G-protein coupled receptors, epidermal growth factor receptor, tyrosinekinase receptor mutation variant III, and protein tyrosine kinasereceptor 7. Additional examples of receptors specific to cancer cellsand corresponding aptamers are well known to a person of ordinary skillin the art and such embodiments are within the purview of thisinvention. For example, Meyer et al. (2011), Cell-specific aptamers asemerging therapeutics, Journal of Nucleic Acids, Volume 2011, Article ID904750, teaches cancer cell receptor specific aptamers, the contents ofwhich are herein incorporated by reference in its entirety,particularly, page 5, section under “Cell specific aptamers for therapy”continuing on to pages 6 to 13.

Examples of aptamers and corresponding diseases that can be treatedusing the aptamers are given in Marolt et al., Generating aptamers forcancer diagnosis and therapy, Clin. Exp. Pharmacol., (2012) 2:111, thecontents of which are herein incorporated by reference in its entirety,particularly, page 3, table 1; page 3, section under “Aptamers in cancercell diagnostics and Treatment” continuing on to page 4; page 4, sectionunder “Aptamers used in alimentary neoplasm, continuing on to pages 5and 6; and FIGS. 1 and 2. Other examples of aptamers and correspondingdiseases that can be treated using the aptamers are given in Meyer etal. (discussed above). A skilled artisan can identify additionaldiseases and corresponding aptamers that can be treated according to thecompositions and methods of the current invention and such diseases arewithin the purview of the current invention.

The subjects that can be treated according to the methods of the currentinvention can be a mammal, for example, a human, porcine, canine,rodent, feline, or bovine.

The pharmaceutically effective amount of the aptamer-polynucleotide stemcomplex-drug conjugate depends on the type of disease to be treated andthe type of drug conjugated to the complex as well as the tolerance ofthe subject for the treatment.

The disease treatment according to the current invention can also beadministered in combination with one or more other treatments. Forexample, cancer in a subject can be treated by administering theNHCM-aptamer conjugate of the current invention in combination withchemotherapy and/or radiotherapy.

In an exemplary embodiment of the invention, the leukemia specificaptamer Sgce8c with a primary amine modification is coupled with acarboxylic acid functional NHCAu complex. Conjugation of a NHCM complexto the aptamer can be carried out with an aptamer, for example, but notlimited to, the leukemia-specific aptamer Sgc8c (5′-ATC TAA CTG CTG CGCCGC CGG GAA AAT ACT GTA CGG TTA GA-3′ SEQ ID NO: 1). For example, thecoupling reagents 1-ethyl-3-[3-dimethylaminopropyl]carbodiimidehydrochloride (EDC), as shown in FIG. 4, and N-hydroxysulfosuccinimide(Sulfo-NHS) can be used to couple the carboxylic acid functionalizedNHCAu complex to the primary amine modified aptamer.

Standard phosphoramidite solid phase DNA synthesis is completelyautomated and highly reproducible, and DNA oligonucleotides are easilypurified. Aptamer synthesis by solid phase phosphoramidite chemistry isamenable to synthetic modifications. By simply inserting anycommercially available phosphoramidite modified with the requisitefunctional group onto either the 3′ or 5′ end of the oligonucleotidesequence, an aptamer can be generated that is complementary for couplingto a NHCM complex.

In an embodiment of the invention, an NHCM complex can have an R groupthat is a fluorescent dye or other functionality that yields anaptamer-NHCM conjugate that can act as a delivery-therapeutic-detectionagent, where the dye is a fluorophore, to facilitate in vivo detection.For example, as shown in FIG. 5, a1-dimethylaminonaphthalene-5-sulfonamidopolymixin (dansp) flourophorefunctionalized NHC-gold complex can be formed and conjugated in themanner of FIG. 4 to form the aptamer-NHCAu conjugatedelivery-therapeutic-detection agent. The dansp moiety fluoresces at 532nm upon excitation at 365 nm. Other fluorescent dyes and molecules canbe adapted for use as the R group, including, but not limited to,pyrenylmethyl, anthracenylmethyl, or any other fluorescent moiety.Alternatively or additionally, the NHCM complex can have an R group thatcomprises a polyether group or other group that can aid in crossing acancer cell membrane and/or increasing the aptamer-NHCM complexessolubility in aqueous media.

METHODS AND MATERIALS

Compounds 1 (shown in FIG. 1) and 7 (shown in FIG. 3) were preparedaccording to reported procedures. Unless stated otherwise all synthesesand manipulations were performed under aerobic conditions. All startingreagents were obtained from either Sigma Aldrich or STREM chemicals andused as received without further purification. (CH₃)₂SAuCl, Ag₂O,glycine were obtained from Sigma Aldrich and used without furtherpurification. Sgc8c-Aptamer was synthesized with a DNA synthesizeraccording to literature procedures.

All oligonucleotides were synthesized based on solid-phasephosphoramidite chemistry at a 1 μmol scale using the ABI3400 DNA/RNAsynthesizer (Applied Biosystems, Foster City, Calif.).¹ Amine coupled atthe 5′-end of oligonucleotides with 6 T group as spacer. A ProStar HPLC(Varian, Walnut Creek, Calif.) instrument with a C18 column (Econosil,5, 250 mm) from Alltech (Deerfield, Ill.) was used to purify allfabricated DNA. The collected sequences were vacuum-dried and quantifiedusing a Cary Bio-300 UV spectrometer (Varian Walnut Creek, Calif.).

Sgc8c: SEQ ID NO: 1 5′-ATC TAA CTG CTG CGC CGC CGG GAA AAT ACT GTACGG TTA GA-3′ AS1411: SEQ ID NO: 25′-GGT GGT GGT GGT TGT GGT GGT GGT GG-3′

All cell lines used in this research were cultured in American TypeCulture Collection recommended medium, with 10% fetal bovine serum(Invitrogen, Carlsbad, Calif.) and 0.5 mg/mL penicillin-streptomycin(American Type Culture Collection) at 37° C. under a 5% CO₂ atmosphere.CCRF-CEM (T-cell line) and K562 (acute promyelocytic leukemia cell) werecultured in RPMI 1640 medium; MDA-MB-231 (breast cancer cells werecultured in L-15 medium; DU145 (prostate cancer cell) was cultured inEMEM medium; Hela (cervical cancer cell), HEK293 (human kidney cell) andHU1545v (human untransformed liver cell) were cultured in DMEM medium.Cells were washed before and after incubation with washing buffer [4.5g/L glucose and 5 mM MgCl₂ in Dulbecco's PBS with calcium chloride andmagnesium chloride (Sigma-Aldrich)]. Binding buffer was prepared byadding yeast tRNA (0.1 mg/mL; Sigma-Aldrich) and BSA (1 mg/mL; FisherScientific) to the washing buffer to reduce background binding. Allreagents for buffer preparation and HPLC purification came from FisherScientific. Unless otherwise stated, all chemicals were used withoutfurther purification.

All NMR spectra were collected on either a Varian Mercury Broad Band 300MHz or Varian Inova 500 MHz spectrometer. Chemical shifts are reportedin δ (ppm) with the solvent peak referenced as an internal reference.The DOSY experiments used bipolar pulse pair stimulated echo withconvection compensation. The gradient length was 1 ms and the diffusiontime 100 ms; the gradient strength was arrayed in 15 steps squarelyspaced from 2 to 53 Gauss/cm. Spectra were collected in 16 scans with anacquisition time of 3.6 s and a relaxation delay of 3 s.

Electrospray Ionization Mass Spectrometry (ESI-MS) data for bothpositive and negative modes were obtained according to the followingprocedure. Samples were dissolved in methylene chloride or in water anddirectly injected into an auto-sampler, where they were subjected to ESIwith methanol as the mobile phase. Ions were detected with an Agilent6210 TOF-MS instrument and the data was processed usingMassHunterTMsoftware.

Synthesis of Compound 9

Bis(1-mesityl-3-(2-carboxylatoethyl)imidazol-2-ylidene)-trans-dichloridegold(III) sodium salt 9 was prepared following the procedure of Dinda etal., New Journal of Chemistry 2013, 37 (2), 431-438 via an in situtrans-metalation reaction. To a 100 mL Schlenk flask under an atmosphereof Ar, 138.0 mg (0.534 mmol) of 7, 130.0 mg (0.561 mmol) of Ag₂O, amagnetic stir bar, and 20 mL of deoxygenated water were added and leftto stir for 24 h at 50° C. in the dark. After 24 h, the reaction mixturewas allowed to cool to ambient temperature whereupon 32.0 mg (0.548mmol) of NaCl was added and allowed to stir for an additional 30 min atroom temperature. The solution was passed through a celite pad and finefrit filter. To the filtrate, 160.0 mg (0.543 mmol) of (CH₃)₂SAu(I)Clwas added and allowed to stir for 24 h at room temperature, in the dark,under an atmosphere of Ar. After 24 h, the reaction mixture was passedthrough a pad of celite and fine frit filter. The filtrate was reducedto 5 mL whereupon the dark purple solution was filtered to remove goldnanoparticles. The remaining solvent was removed in vacuo to give anoff-white residue (62.8 mg, 30.1%). ¹H-NMR (DMSO-d₆, 300 MHz). δ=7.75(d, J=1.75 Hz, 2H), 7.38 (d, J=1.75 Hz, 2H), 6.99 (s, 4H), 4.30 (t,J=6.87 Hz, 4H), 2.41 (t, J=6.87 Hz, 4H), 2.40 (s, 6H), 1.72 (s, 12H).ESI-MS (positive ion, calculated for M=C₃₀H₃₅AuCl₂N₄O₄). 827.1440 m/z[M−H+2Na]⁺, 805.1616 m/z [M+Na]⁺, 783.1797 m/z [M+H]⁺, 769.1852 m/z[M−HCl+Na]⁺. ESI-MS (negative ion) 817.1222 m/z [M+Cl]⁻, 803.1450 m/z[M−2H+Na]⁻, 781.1640 [M−H]⁻, 709.1415 m/z [M−C₃H₅O₂]⁻, 637.1200 m/z[M+H−2C₃H₅O₂]⁻, 338.8382 m/z [AuCl₃+Cl]⁻, 266.9032 m/z [AuCl₂−Cl]⁻

Imidazolium chloride salt 10 was prepared via alkylation with benzylchloroacetate, as shown in FIG. 6. Generating the benzyl protectedsilver(I) complex 11 in situ followed by transmetalation, as shown inFIG. 7, with (CH₃)₂SAuCl provides complex 12, which is confirmed by¹H-NMR spectroscopy. The ions detected in positive mode ESI-MS analysissupport the assignment of 12 as the benzyl ester protected monocarbenegold(I)-NHC complex 12.

Alkyne functionalized heterocycles 13-15, were prepared under theconditions shown in FIG. 8, where relatively harsh conditions arerequired to drive the reaction. Using a relatively high temperature(120° C.) and long reaction time (3 days), the method permitted theassembly of ligands 13-15 in yields of 63.4, 80.2, and <25%,respectively. ¹H-NMR spectra of 13-15 reveal diagnostic downfieldchemical shifts of 10.0-10.5 ppm, corresponding to the deshielded C₂proton flanked by two nitrogen atoms of the imidazol-2-ylidene ring.¹³C-NMR spectra of these ligands exhibit resonances attributable to theC₂ carbons between 135.7 ppm and 137.9 ppm. The terminal alkynyl protonsof ligands 14 and 15 appear as triplets (J=2.2-2.7 Hz) due to long rangecoupling with the methylene protons distal to the heterocyclic ring andadjacent to the triple bond. This long range coupling is still presentfor compound 13 but is not viewable by ¹H-NMR spectroscopy due to signaloverlap with a large singlet at 2.05 ppm from the mesityl methyl groups.

Deprotonation and metalation of ligand 13, as shown in FIG. 9, with 0.70equivalents of silver(I)oxide required long reaction times. Aliquots ofthe reaction mixture taken periodically throughout the duration of thereaction and subjected to ¹H-NMR spectroscopic analysis, as shown inFIG. 10, provided a method of monitoring the reaction progress. Theligand's C₂ imidazolium proton, resonating at 10.15 ppm, decreases overtime concomitant with the growth of a set of resonances in the aromaticand aliphatic regions corresponding to complex 16. Total conversion of13 to the silver(I) species 16 requires stirring at room temperature forthree full days in the absence of light. Precipitation of complex 16 asa fine tan powder resulted from passing the reaction mixture throughcelite, reducing the filtrate by vacuum, and adding an excess of ether.The ¹H-NMR spectrum of 16 provides evidence that the C₂ proton of 13 wasremoved. Though the lack of resonances downfield of 10 ppm in the ¹H-NMRspectrum of 16 indicates a complex form, the weak and seemingly absent,chemical shift in the range of 170 ppm and 190 ppm (commonly reportedfor NHC silver(I)-carbene complexes) in the ¹³C-NMR spectrum of complex16, prompted further characterization.

Data suggest that the more labile (exchanging) a silver-carbene bond ison the NMR time scale, the broader the ¹³C NMR signal of the carbenecarbon. In the case of complex 16, the weak, almost indistinguishablesignal, is the result of broadening and baseline saturation caused by arelatively labile silver-carbene bond. To establish the structure of 16in solution, gradient heteronuclear multiple bond coherence (gHMBC)experiments were performed to elucidate C—H connectivities and confirmpeak assignments. Long range coupling between the carbene carbon (182.9ppm) of the imidazol-2-ylidene ring and the proximal methylene protonsof the of the alkyne (4.38 ppm) N-substituent as well as the C4 and C5protons of the imidazolium ring (6.92 and 7.36 ppm). The lack of a >200ppm ¹³C-NMR chemical shift in conjunction with a detected resonance at182.9 ppm, precludes the possibility of a free carbene and supports theassignment of a silver(I)-NHC complex.

Transmetalation of complex 16 to gold(I) proceeds rapidly upon treatmentof the silver(I) species with 1.2 eq of chlorodimethylsulfide gold(I),as shown in FIG. 11. Solid AgCl immediately precipitates as the gold(I)ion coordinates and displaces silver(I) from the carbene carbon of theNHC ligand. Complete conversion of 16 to 17 requires only 15 minutes, asmonitored by ¹H and ¹³C-NMR spectroscopy. A diagnostic gold(I)-carbene¹³C-NMR resonance of 172.0 ppm appears, along with new chemical shiftsacross the remainder of the spectrum.

Transmetalation proceeds rapidly and reaction times exceeding 1 h leadto the appearance of colloidal gold accompanied by a purple colorchange. Although this color change is indicative of complexdecomposition or possible product conversion, no observable demetalationproducts (i.e., free ligand resonances) are observed spectroscopically;in fact, both the ¹H and ¹³C-NMR spectra still indicate the presence ofonly one clean product in solution. An explanation for this phenomenonis that the decomposition products are comprised exclusively of NMRsilent and/or chloroform insoluble species. To probe whether theappearance of colloidal gold forms as a consequence of a monocarbene tobiscarbene conversion, or an oxidation state change from gold(I) togold(III), a succinct NMR study was performed. The reaction of FIG. 11was repeated on an NMR scale with 30 mg of 16. ¹H and ¹³C NMR spectraobtained at variable time intervals indicate the initial transmetalationfrom silver(I) to gold(I) occurs with a clear ¹³C-NMR signal shift from˜184 to 172 ppm. The data support immediate formation of a singlespecies that does not undergo subsequent mono- to bis-NHC conversion ormetal ion oxidation processes.

Synthesis of Compound 10

1-Mesityl-3-(2-benzyleacetyl) imidazolium chloride 10 was prepared byadding compound 1′ (0.640 g, 3.44 mmol), a magnetic stir bar, and 4 mLof dry toluene to a 250 mL round bottom flask. The mixture was allowedto stir for 2 min, whereupon benzyl chloroacetate 2′b (0.53 mL, 3.44mmol) was added dropwise. The system was placed under Ar and heated to110° C. for 6 h while stirring. The mixture was then allowed to cool andleft to stir for an additional 12 h at room temperature. The solvent wasremoved in vacuo and the resulting colorless solid was triturated withether (1.02 g, 79.9%). ¹H-NMR (CDCl₃, 300 MHz) δ=10.41 (s, 1H), 7.94 (m,1H), 7.34-7.32 (5H, m), 7.08 (m, 1H), 6.95 (s, 2H), 5.98 (s, 2H), 5.18(s, 2H), 2.32 (s, 3H), 2.01, (s, 6H). ¹³C-NMR (CDCl₃, 125 MHz). δ=166.4(C═O), 141.3, 139.7 (NCN), 139.7, 134.30, 134.3, 130.6, 129.7, 128.7,128.6, 124.4, 122.3, 68.38, 50.57, 21.04, 17.39.

Synthesis of Compound 12

1-Mesityl-3-(2-benzyleacetyl)imidazolium gold(I) chloride 12 wasprepared via an in situ transmetalation reaction. 0.201 g of 10 and0.150 g of Ag₂O were suspended in 5 mL of dichloromethane and allowed tostir for 24 h in the dark. The resulting suspension was passed through acelite pad and fine frit filter directly into a stirring suspension of0.075 g of (CH₃)₂SAu(I)Cl in 5 mL of dicholoromethane. The reactionmixture was allowed to stir at room temperature for 3.5 h in the dark.The mixture was then passed through a celite pad and medium frit toyield an amber colored filtrate. The solvent was concentrated and thentreated with an excess of pentanes to precipitate a fine off-whitepowder. ¹H-NMR (CDCl₃, 300 MHz) δ=7.38 (m, 5H), 7.23 (d, J=1.32 Hz, 1H),6.95 (s, 2H), 6.92 (d, J=1.32 Hz, 1H), 5.24 (s, 2H), 5.14 (s, 2H), 2.32(s, 3H), 1.99, (s, 6H). ESI-MS (positive ion, calculated forM=C₂₁H₂₂N₂O₂AuCl). 1155.1945 m/z [2M+Na]⁺, 1097.2374 m/z [2M−Cl]⁺,589.0926 m/z [M+Na]⁺, 531.1339 m/z [M−Cl]⁺.

Hydrogenolysis Reaction

Compound 12 (30 mg) was dissolved in a 1:1 mixture of methanol: ethylacetate (10 mL). This mixture was added to a solution of 1:1 methanol:ethyl acetate (5 mL) containing 5 mg of Pd/C. The reaction mixture wasleft to stir at room temperature under a balloon of H₂ for 24 h. Afterthe allotted time, the solution was passed through a celite pad and finefrit. The solvent was removed in vacuo and a ¹H-NMR of the residue wasobtained (CDCl₃, 300 MHz) and indicated the presence of only startingmaterial 12.

Synthesis of Compound 13

1-Mesityl-3-(1-butyne)imidazolium bromide 13 was prepared by dissolving1.11 g (5.95 mmol) of 1-mesitylimidazole in 10 mL of toluene in a 100 mLround bottom flask. To this stirring solution, 0.84 mL (8.92 mmol) ofcold 4-bromo-1-butyne was added dropwise. The reaction mixture was thenplaced under an ice water cooled condenser, heated to 120° C., andallowed to stir at this temperature for 3 d. After the reaction wascomplete an off-white residue formed a film on the inside of thereaction vessel. 20 mL of diethyl ether was added directly to thereaction mixture and the contents were stirred vigorously for 3 h atroom temperature. The suspension was filtered and the solid wascollected on a Buchner funnel and washed with 3×10 mL of diethyl ether.The resulting off-white solid was then dried under vacuum for 24 h (0.70g, 63.4%). Heteronuclear multiple bond coherence (gHMBC) was applied todetermine C—H connectivities and confirm peak assignments. ¹H-NMR(CDCl₃, 500 MHz) δ=10.15 (s, 1H), 8.23 (s, 1H), 7.17 (s, 1H), 6.97 (s,2H), 4.89 (t, J=5.85 Hz, 2H), 2.99 (dt, J=5.85 Hz, J=1.95 Hz, 2H), 2.31(s, 3H), 2.05 (s, 6H), 2.05 (t, J=1.95 Hz, 1H). ¹³C-NMR (CDCl₃, 125MHz): δ=141.3, 137.9 (NCN), 134.2, 130.6, 129.8, 123.9, 122.7, 79.06,72.54, 48.56, 21.07, 21.04, 17.56. ESI-MS (positive ion, calculated forM=C₁₆H₁₉BrN₂). 355.0402 m/z [M+Cl]⁺, 319.0802 m/z [M+H]⁺, 239.1554 m/z[M−Br]⁺.

Synthesis of Compound 14

1-Benzyl-3-(1-butyne)imidazolium bromide 14 was prepared by a similarsynthetic procedure as 13 using 1.00 g (6.32 mmol) of1-benzyl-imidazole, 0.71 mL (7.59 mmol) of 4-bromo-1-butyne, and 15 mLof toluene. The resulting off-white powder was collected on a Buchnerfunnel and dried under vacuum for 24 h (1.48 g, 80.2%). Heteronuclearmultiple bond coherence (gHMBC) was applied to determine C—Hconnectivities and confirm peak assignments. ¹H-NMR (CDCl₃, 500 MHz)δ=10.45 (s, 1H), 7.75 (s, 1H), 7.45 (d, J=1.6 Hz, 2H), 7.42 (s, 1H),7.34 (d, J=1.6 Hz, 2H), 7.33 (d, J=1.6 Hz, 1H), 5.57 (s, 2H), 4.51 (t,J=6.3 Hz, 2H), 2.84 (dt, J=6.3 Hz, J=2.6 Hz, 2H), 2.08 (t, J=2.6 Hz,1H). ¹³C-NMR (CDCl₃, 125 MHz): δ=137.1 (NCN), 132.8, 129.5, 129.4,128.9, 122.8, 121.6, 78.69, 72.90, 53.35, 48.42, 20.79. ESI-MS (positiveion, calculated for M=C₁₄H₁₅BrN₂). 327.0070 m/z [M+Cl]⁺, 291.0484 m/z[M+H]⁺, 211.1238 m/z [M+Br]⁺.

Synthesis of Compound 15

1-tert-Butyl-3-(1-butyne)imidazolium bromide 15 was prepared by asimilar synthetic procedure as 13 but with a slightly modified work-up.The synthesis was performed using 1.11 mL (8.05 mmol) of1-(tert-butyl)-imidazole, 1.13 mL (12.1 mmol) of 4-bromo-1-butyne, and10 mL of toluene. After the reaction was complete, the mixture wasallowed to cool to room temperature and 20 mL of diethyl ether was addeddirectly to the reaction vessel. The mixture was stirred for 10 min andthe supernatant was decanted. The off-white residue was resuspended in10 mL of fresh diethyl ether, stirred for 10 min and the supernatant wasdecanted (this was repeated 2 more times). After the final decanting,the solid was suspended in 2 mL of diethyl ether, transferred directlyto a vial. The remaining solvent was removed in vacuo and the resultingoff-white, very hygroscopic solid was dried under vacuum for 24 h beforetransferring to an Ar filled glovebox for storage (0.453 g, 21.9%).¹H-NMR (CDCl₃, 300 MHz) δ=10.47 (s, 1H), 7.75 (s, 1H), 7.55 (s, 1H),4.62 (t, J=6.3 Hz, 2H), 2.88 (dt, J=6.3 Hz, J=2.2 Hz, 2H), 2.07 (t,J=2.2 Hz, 1H), 1.68 (s, 9H). ¹³C-NMR (CDCl₃, 125 MHz): δ=135.7 (NCN),123.0, 119.2, 79.07, 72.38, 60.38, 48.04, 29.99, 20.77.

Synthesis of Compound 16

1-Mesityl-3-(1-butyne)imidazol-2-ylidene silver(I) bromide 16 wasprepared by deprotonation and direct metalation with silver(I) oxide.Inside an Ar filled glovebox, 303.0 mg (0.949 mmol) of compound 13 wasadded to a vial and dissolved in 4 mL of chloroform. 151.1 mg (0.652mmol) of silver(I) oxide was added directly as a solid to this stirringsolution. The reaction vessel was wrapped in aluminum foil and allowedto stir for 3 d at room temperature. The reaction mixture was passedthrough a pad of celite atop a filter paper fitted glass pipette toremove any insoluble gray particulates. The amber colored filtrate wasreduced in vacuo to 1 mL whereupon an excess of diethyl ether (˜5 mL)was added to precipitate an off-white solid. The supernatant wasdecanted, the solid was resuspended in 2 mL of diethyl ether, and thesupernatant was decanted again (this was repeated 2 more times with 2×2mL of diethyl ether). The solid was dried completely under vacuum togive an off-white solid (264.5 mg, 65.4%). Heteronuclear multiple bondcoherence (gHMBC) was applied to determine C—H connectivities andconfirm peak assignments. ¹H-NMR (CDCl₃, 500 MHz) δ=7.36 s, 1H), 6.94(s, 2H), 6.92 (s, 1H), 4.38 (t, J=6.3 Hz, 2H), 2.76 (dt, J=6.3 Hz, J=1.7Hz, 2H), 2.33 (s, 3H), 2.04 (t, J=1.7 Hz, 1H), 1.94 (s, 6H). ¹³C-NMR(CDCl₃, 125 MHz): δ=182.9 (C_(carbene)), 139.5, 135.4, 134.7, 129.4,122.5, 121.4, 79.72, 72.17, 50.16, 21.87, 21.06, 17.63.

Synthesis of Compound 17

1-Mesityl-3-(1-butyne)imidazol-2-ylidene gold(I) halide 17 was preparedby a transmetalation reaction from compound 16. The following steps wereperformed inside an Ar filled glovebox and taking care to minimize lightexposure. 152.3 mg (0.357 mmol) of compound 16 was dissolved in 4 mL ofchloroform. To this stirring mixture, 126.3 mg (0.429 mmol) ofchlorodimethylsulfide gold(I) was added directly as a solid over thecourse of 2 min whereupon a white solid immediately precipitated. Thereaction vessel was capped and left to stir in the dark at roomtemperature for 1 h. The cloudy grayish purple reaction mixture waspassed through a celite pad atop a filter paper fitted glass pipette inan attempt to remove the colloidal gold. The filtrate was reduced to 1mL under vacuum and an excess of diethyl ether was added to precipitatea bright white solid. The supernatant was decanted and the solid wasresuspended in diethyl ether (3 mL). This was repeated two more times(2×3 mL diethyl ether). An accurate yield could not be obtained due tointractable colloidal gold. Heteronuclear multiple bond coherence(gHMBC) was applied to determine C—H connectivities and confirm peakassignments. ¹H-NMR (CDCl₃, 500 MHz) δ=7.31 (d, J=1.39 Hz, 1H), 6.94 (s,2H), 6.86 (d, J=1.39 Hz, 1H), 4.41 (t, J=6.35 Hz, 2H), 2.84 (dt, J=6.35Hz, J=2.58 Hz, 2H), 2.31 (s, 3H), 2.07 (t, J=2.58 Hz, 1H), 2.00 (s, 6H).¹³C-NMR (CDCl₃, 125 MHz): δ=172.0 (C_(carbene)), 139.7, 134.7, 134.7,129.4, 121.8, 121.3, 79.52, 72.02, 49.68, 21.40, 21.08, 17.73.

Synthesis of 19

Inside an Ar filled glovebox, solid ligand 18 (260 mg, 0.6 mmol, 1equiv.) and Ag₂O (97.32 mg, 0.4 mmol, 0.7 equiv.) were dissolved indichloromethane (10 mL) and stirred for 2 days to provide the NHC—Agcomplex 19 in situ. To the reaction mixture was added (CH₃)₂SAuCl(176.73 mg, 0.6 mmol, 1 equiv.) and stirred for 1 h. Then the reactionmixture was filtered through Celite®. The filtrate was collected andreduced under vacuum to 1 ml. Diethyl ether was added to precipitate apale yellow powder. The solid was collected by filtration and driedunder vacuum for 2 h to provide the NHC—Au complex 19 (112.5 mg,Yield=45%). ¹H NMR (300 MHz, CDCl3): δ=8.18 (s, 2H, HAr), 7.29-7.53 (m,6H, HAr), 5.84 (s, 2H, N—CH₂), 4.13 (s, 3H, N—CH₃) ppm. ¹³C NMR (CDCl₃,500 MHz): δ=179.6 (NCN), 161.9 (COO), 141.5 (C—Ar), 136.1 (C—F), 134.4(C—F), 134.1 (C—Ar), 132.7 (C—F), 132.7 (C—Ar), 131.5 (C—Ar), 127.2(C—Ar), 125.1 (C—Ar), 125.0 (C—Ar), 119.9 (C—Ar), 116.6 (C—Ar), 111.7(C—Ar), 52.3 (N—C—Ar), 35.4 (N—CH₃) ppm. ¹⁹F NMR (CDCl₃, 235 MHz):δ=−152.77 (t, ³J_(F,F)=19.1 Hz, 2 F, ArF), −158.05 (t, ³J_(F,F)=23.2 Hz,1 F, ArF), −162.55 (dd, ³J_(F,F)=19.1, 23.2 Hz, 2 F, ArF) ppm. Anal.Calcd for C₂₂H₁₃AuClF₅N₂O₂ (664.03 g mol⁻¹): C: 39.75%; H: 1.97%; N:4.21%, Found: C: 39.89%; H: 2.10% N: 4.42%.

Synthesis of aptamer-drug conjugate1-(methyl)-3-(4-N-sgc8c-aptamer-carbamoylbenzyl)benzo[d]imidazoliumgold(I) chloride 21

In a 2 ml synthesis tube, complex 19 (6 mg, 9 μmol) was dissolved in 1ml THF, and triethylamine (1 mg, 9 μmol) was added drop wise. After 10min of shaking, 1 ml aqueous solution of aptamer 20 (0.1 μmol) was addedto the tube, and the mixture was shaken for 24 h. Then the reactionmixture was separated and purified by HPLC and gel electrophoresis.

Synthesis of 1-(anthracen-9-ylmethyl)-1H-benzo[d]imidazole (24)

The mixture of benzimidazole 22 (354 mg, 3 mmol), tetrabutylammoniumbromide (TBAB) (96 mg, 0.3 mmol), THF (10 mL) and 50% aqueous K2CO3 (10mL) was stirred. 9-(chloromethyl)anthracene 23 (678 mg, 3 mmol) wasadded in portions. Then, the mixture was heated to 70° C. for 40 h.After heating the mixture was cooled to room temperature and extractedby dichloromethane (DCM). The organic layer was dried with NaSO₄. Thesolvent was removed in vacuo to give compound 24 as a yellow solid. (700mg, Yield=76%). ¹H NMR (300 MHz, CDCl3): δ=8.63 (s, 1H, N—CH—N), 8.10(s, 4H, HAr), 7.82-7.37 (m, 9H, HAr), 6.21 (s, 2H, N—CH₂). ¹³C NMR(CDCl₃, 500 MHz): δ=143.93 (NCN), 142.14 (C—Ar), 134.18 (C—Ar), 131.40(C—Ar), 129.69 (C—Ar), 129.48 (C—Ar), 127.52 (C—Ar), 125.38 (C—Ar),122.92 (C—Ar), 122.41 (C—Ar), 120.50 (C—Ar), 109.49 (C—Ar), 41.34(N—CH₂) ppm.

Synthesis of 26

To a solution of 24 (500 mg, 1.6 mmol) in dry THF (10 mL) was addeddropwise a solution of 25 (610 mg, 1.6 mmol) in THF (10 mL). Aftercomplete addition, the mixture was refluxed for 48 h during which time ayellow precipitate formed. The solvent was decanted from the precipitateand the solid was washed with THF (3×10 mL) and then dried in vacuo togive a yellow solid 26 (504 mg, 51% yield). ¹H NMR (300 MHz, CDCl3):δ=12.03 (s, 1H, N—CH—N), 8.57-8.64 (m, 3H, HAr), 8.15 (m, 4H, HAr),7.67-7.41 (m, 9H, HAr), 7.13 (m, 1H, HAr), 6.89 (s, 2H, CH₂-anthracene),6.07 (s, 2H, CH₂—Ar) ppm. ¹⁹F NMR (CDCl₃, 300 MHz): δ=−152.38 (t,³J_(F,F)=19.1 Hz, 2 F, ArF), −157.53 (t, ³J_(F,F)=23.2 Hz, 1 F, ArF),−162.09 (dd, ³J_(F,F)=19.1, 23.2 Hz, 2 F, ArF) ppm.

DART-MS (positive ion, calculated for M=C₃₆H₂₂BrF₅N₂O₂). 609.1612 m/z[M+H]+.

Synthesis of1-(anthracen-9-ylmethyl)-3-(4-N-sgc8c-aptamer-carbamoylbenzyl)benzo[d]imidazolium gold(I) chloride 27

Inside an Ar filled glovebox, solid ligand 26 (100 mg, 0.16 mmol, 1equiv.) and Ag₂O (26 mg, 0.11 mmol, 0.7 equiv.) were dissolved in DCM (5mL) and stirred for 2 days to provide the NHC—Ag complex in situ. To thereaction mixture was added (CH₃)₂SAuCl (50 mg, 0.16 mmol, 1 equiv.) andstirred for 1 h. Then, the reaction mixture was filtered throughCelite®. The filtrate was collected and reduced under vacuum to 0.5 ml.Diethyl ether was added to precipitate a pale yellow powder. The solidwas collected by filtration and dried under vacuum for 2 h to providethe NHC—Au complex 27 (98 mg, Yield=71%). ¹H NMR (300 MHz, CDCl3):δ=8.63-8.53 (m, 3H, HAr), 8.13 (m, 4H, HAr), 7.63-7.49 (m, 6H, HAr),7.15 (m, 2H, HAr), 6.84 (s, 2H, N—CH₂-anthracene), 5.92 (s, 2H,N—CH₂—Ar) ppm. ¹³C NMR (CDCl₃, 500 MHz): δ=180.55 (NCN), 161.9 (COO),141.5 (C—Ar), 136.1 (C—F), 134.4 (C—F), 134.1 (C—Ar), 132.7 (C—F), 132.7(C—Au), 161.87 (COO), 141.54 (C—Ar), 133.44 (C—Ar), 131.42 (C—Ar),129.87 (C—Ar), 127.64 (C—Ar), 127.37 (C—Ar), 125.35 (C—Ar), 124.64(C—Ar), 123.20 (C—Ar), 122.03 (C—Ar), 112.98 (C—Ar), 111.46 (C—Ar),52.36 (N—C-Antracene), 47.90 (N—CH₂—Ar) ppm. 19F NMR (CDCl₃, 235 MHz):δ=−152.32 (t, ³J_(F,F)=19.1 Hz, 2 F, ArF), −157.66 (t, ³J_(F,F)=23.2 Hz,1 F, ArF), −162.15 (dd, ³J_(F,F)=19.1, 23.2 Hz, 2 F, ArF) ppm. DART-MS(positive ion, calculated for M=C₃₆H₂₂AuClF₅N₂O₂). 858.1236 m/z[M+NH₄]+.

Synthesis of1-(anthracen-9-ylmethyl)-3-(4-N-sgc8c-aptamer-carbamoylbenzyl)benzo[d]imidazolium triphenylphosphino gold(I) tetrafluoroborate 31

As indicated in FIG. 21, a 100 mg portion of complex 27 was dissolved in5 ml of acetone, then 35 mg of triphenylphophine (0.133 mmol, 1.1equiv.) and 24 mg of KPF₆ (0.133 mmol, 1.1 equiv.) were added. Themixture was stirred at room temperature for 1 hour. After which, themixture was filtered through Celite and the filtrate was dried undervacuum. The yellow residue was dissolved in 2 ml of DCM and washedseveral times with water, then 10 ml of hexane was added to the organicsolution to precipitate the cationic NHC—Au complex 29. Complex 29 waspurified by washing with hexane for 3 times (0.112 g, yield=81.7%). %).¹H NMR (300 MHz, CDCl₃): δ=8.21 (d, 2H, HAr), 8.05 (s, 1H, HAr), 7.94(d, 2H, HAr), 7.79 (m, 3H, HAr), 7.55 (m, 9H, HAr), 7.41 (m, 10H, HAr),7.16 (d, 2H, HCAr), 6.56 (s, 2H, CH₂-antrancene), 5.86 (s, 2H,CH₂-benzyl) ppm. ¹³C{¹H} NMR (CDCl₃, 125 MHz): δ=194.01 (C—Au), 193.03(C—Au), 162.00 (C═O), 142.56 (C—Ar), 138.49 (C—Ar), 138.03 (C—Ar),134.11 (C—Ar), 131.39 (C—Ar), 129.40 (C—Ar), 127.56 (C—Ar), 125.42(C—Ar), 123.05 (C—Ar), 112.27 (C—Ar), 52.12 (CH₂-antrancene), 42.09(CH₂-benzyl) ppm. ³¹P NMR (CDCl₃, 121 MHz): δ=106.10 (q, PF₆), 38.34 (s,Au—PPh₃) ppm. DART-MS (positive ion, for M+=C₅₄H₃₆AuF₅N₂O₂P). [M]⁺ calcdfor 1067.2095; Found: 1067.2101.

Synthesis and Biology Assay of Aptamer-Drug Conjugates

A NH₂-modified sgc8c aptamer was synthesized and purified based on thatreported in Shangguan et al. Clin. Chem. 2007, 53(6), 1153-5. As shownin FIG. 12, aptamer 20 was treated with 100 equivalent of the NHC—Aucomplex 19 and 100 equivalent trimethylamine in THF/Water (1/1) at roomtemperature. After two days, the reaction mixture was purified by gelelectrophoresis and HPLC. The conjugation reaction between the ligand 18and sgc8c aptamer 20 was conducted under the same conditions to giveconjugate 28.

Synthesis of an Anthracene Dye-Tagged NHC—Au Complexes

As a tool for monitoring the uptake of the metal-aptamer conjugate andfor confirming successful conjugation to the aptamer, a dye was taggedto the Au complex, as indicated in FIG. 14

As shown in FIG. 14, 9-(chloromethyl)anthracene 23 and benzimidazole 22were stirred in THF and aqueous K₂CO₃ solution (1:1) for 2 days, formingthe yellow-brown solid 24. Then compound 25 was added to produce ligandprecursor 26 as a yellow solid. The metallation reaction gave compound27 as a yellow powder. Compound 27 has a blue fluorescence under 365 nmUV light. The luminescent spectrum of the NHC-Gold compound 27 wasmeasured by dissolving 1 mg of 27 in 1 ml acetonitrile, as shown in FIG.15.

Synthesis of a Fluorescein Dye-Tagged Aptamer

The coupling of fluorescein isothiocyanate (FITC) to NH₂-modified sgc8captamer was carried out. The FITC-sgc8c aptamer exhibits yellow-greenfluorescence under 365 nm UV light, as does FITC shown in FIG. 16.

Synthesis of Aptamer-Dye-Drug NHC—Au Conjugate

FITC-sgc8c aptamer on the solid support bead were treated with 100equivalent of triethylamine and 100 equivalent of compound 27 in THF asindicated in FIG. 17. The reaction was carried out for 18 h at roomtemperature, after which excess 27 and triethylamine were washed fromthe solid support beads. The beads, which have the aptamer and reactionproducts attached thereto, were incubated with 2 ml ammonium hydroxideand methylamine solution (1:1) at 65° C. for 20 min to release theconjugate. The crude product was purified by high performance liquidchromatography.

Pure FITC-sgc8c aptamer, has a retention time by HPLC of 16 min. Afterreaction, a concentrated component peak for the aptamer-dye-drug NHC—Auconjugate 30 (sgc8c-27) has a retention time of 24 min. This componentwas collected and dried. In the spectrum, shown in FIG. 18, emissionpeaks for FITC and the emission peak of 27 are observed.

Cell Viability Studies

Cell Culture:

Cell lines CEM (T cell leukiemia) and Ramos (Burkitt's Lymphoma) werecultured according to ATCC specifications in RPMI-1640 medium. Themedium was supplemented with 10% fetal bovine serum (Invitrogen) and thecells were incubated at 37° C. in 5% CO₂.

Cytotoxicity Studies Using MTS Assay:

CEM and Ramos cells were treated at the following concentrations ofcompound 9 that were prepared by dilution of an aqueous solution of 20mM 9: 0.5 μM, 1.0μ, 3.5μ, 5.0μ, 7.5μ, 10μ, 15μ, and 25 μM, respectively,for 48 h at 37° C. In addition to treatments, two negative controls,cells in media and water (0.01%) treated cells, were carried out.Approximately 30 μL of 10,000 freshly collected CEM cells were added toeach well of a 96-well plate. Similarly, Ramos cells were added to aseparate 96-well plate. Both plates were incubated at 37° C. in 5% CO₂for 24 h before beginning experiments. After 24 h incubation, 30 μL ofeach concentration of 9 was added to eight wells of each of the 96-wellplates and to a third plate with wells containing no cells (30 L ofmedia for background measurements). Each of the three plates wassubjected to treatment and incubated for 48 h at 37° C. in 5% CO₂. After48 h, 30 μL of MTS dye,(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium),were added to each well. The assay was allotted 4 h at 37° C. fordevelopment. After incubation with the MTS dye, the 490 nm absorbancewas read on a Tecan plate 110 reader for each well. Each cellmeasurement had the treatment background subtracted before analysis.Quantitative and statistical analyses were done using the Origin 8.5software. The same procedures were used to study compound 27 to assesswhether the proligand displayed any cytotoxicity.

A cell viability assay to measure the cytotoxicity of the aptamer-drugconjugate 21 and aptamer-ligand conjugate 28 were performed, asindicated in FIG. 13. The aptamer-drug conjugate 21 efficiently killed50% CCRF-CEM cells in 24 h at a concentration of 600 nM, which is a muchhigher efficiency than complex 19. The IC₅₀ for the aptamer-ligandconjugate 28 is only 1200 nM. MTS assays were conducted as follows. ForCCRF-CEM and K562 cells, 100 μL of 30000 freshly collected cells wereseeded into each well of a 96-well plate, and then incubated withdifferent concentration of the tested compound. After 4 h of incubation,the mixture was centrifuged and 80 μL of old media was removed from eachwell. Then, 200 uL of fresh media was added to each well for another 48h incubation under at 37° C. in a 5% CO₂ atmosphere. For the otheradherent cells (MDA-MB-231, HeLa, PC-3 DU145, HEK293, HU1545v), cellswere suspended in medium and were seeded into 96-well plates andcultured for 24 h. The medium was replaced with fresh medium (no fetalbovine serum) containing the free NHC—Au drug or the preparedaptamer-drug conjugate at different concentrations. Cells were furthercultured for 4 hours to allow the uptake of the drug and aptamer drugconjugate. After which, cells were washed twice with PBS and freshmedium were added for another 48-hours incubation. For all the cells,after 48 h incubation, the mixture in each well was centrifuged toremove all the supernatant, and then each well was treated with 100 uLof MTS dye(MTS=3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)diluted with fresh media with no phosphatidyserine. The assay wasallotted 2 h at 37° C. for development, and then the 490 nm absorbanceof each well was collected on a Tecan plate 110 reader. Each cellmeasurement had the treatment background subtracted before analysis.Cells in media and DMSO (0.01%) alone were used as a control. The IC₅₀values were calculated as the concentrations reducing proliferation ofuntreated control cells by 50% and are given as the means and errors of2-3 independent experiments. FIG. 19A-19B shows an MTS assay of complex27 and conjugate 30 with CCRF-CEM cell lines, and of complex 27 withK562 cell line. FIG. 20 compares the cytotoxicity between NHC—Aucomplexes 19 and 27 and their corresponding conjugates 21 (sgc8c-19) and30 (sgc8c-27). The MTS cell proliferation assay results demonstrate thespecific cytotoxicity of complex 29 and its conjugate 31 (sgc8c-29)towards CCRF-CEM cells CCRF-CEM and K562 cells is shown in FIG. 22. FIG.23 tabulates MTS cell proliferation assay results of cancer cell linesand normal cell lines after treated with cationic NHC—Au complex 29 and32 (AS1411-29) conjugate. AS1411 aptamner was used as a control. Thecytotoxicity of complex 29 is greatly improved (>6 fold) afterconjugated to the nuceleolin targeted aptamer AS1411. FIGS. 24A and 24Bindicates cell viability of MDA-MB-231, HU1545 and HEK293 afterincubation with NHC—Au complex 29 and conjugate 32 (AS1411-29). FIGS.25A-25E show the results of the MTS assay of complex 29 with MDA-MB-231,DU145, HEK293, Hela, and HU1545v cell lines, respectively. FIGS. 25F-25Hshow the results of the MTS assay of conjugate 32 (AS1411-29) withMDA-MB-231, DU145, Hela cell lines, respectively.

Flow Cytometry Analysis was conducted as follows. Cells were plated in a35 mm cell culture dish (Corning Incorporated, Corning, N.Y., USA) andgrown to around 80% confluency for 24 h before the experiments. Cellswere washed twice with 1 mL PBS and then incubated with the preparedaptamer-drug conjugate and LIB-drug conjugate at the concentration of250 nM for 2 h at 4° C. After incubation, cells were washed with washingbuffer three times, dispersed in 80 μL binding buffer, and finallysubjected to flow cytometry analysis using a FACScan cytometer (BectonDickinson Immunocytometry Systems, San Jose, Calif., USA). Fluorescencewas determined by counting 30,000 events, and data were analyzed withFlowJo software.

Flow cytometry assays of conjugate 30 (sgc8c-27) with the K562 cell line(left) and the CCRF-CEM cell line are shown in FIGS. 26A and 26B,respectively. Random aptamer sequences conjugated to 27 to create LIB-27were used as negative control. CCRF-CEM cells incubated with aptamersgc8c and the conjugate 28, which can target CCRF-CEM cells exhibitfluorescence intensity increases. In Similar manner, flow cytometryanalysis of MDA-MB-231 cell, PC3 cell, HEK293 cell and HU1545 cell,FIGS. 27A-27D, respectively, after incubated with 32 (AS1411-29) wereconducted. AS1411 aptamer was used as positive control, and randomlibrary sequences was used as negative control. Target cell MDA-MB-231and PC-3 show much higher enhancement of fluorescence intensity than thenormal cell HEK293 and HU1545 cells.

Confocal microscopy was carried out with cellular fluorescent imagescollected on a Leica TCS SP5 confocal microscope (Leica MicrosystemsInc., Exton, Pa.) with a 63× oil immersion objective and Leica ConfocalSoftware. Cells were treated with 500 nM aptamer-drug conjugate orLIB-drug conjugate, respectively, in serum-free cell culture medium,incubated in a cell culture incubator for 2 h, followed by washing withDulbecco's PBS. The resultant cells were then observed by confocalmicroscopy. FIG. 28A shows the confocal microscopy images of CEM cellsincubated with 30 (Sgc8c-27) for 4 h at 37° C. where the Sgc8c aptamerand LIB sequences were labelled with fluorescein and FIG. 28B is that ofCEM cells incubated by the same procedure with LIB-27. In like manner,confocal microscopy images of K562 cells incubated with 30 (Sgc8c-27)and LIB-27 are shown in FIGS. 28C and 28D, respectively. Only the cellstreated with 30 exhibit appreciable internalization of the conjugate. InSimilar manner confocal microscopy images of HeLa cells and HU1545 cellstreated with 32 (AS1411-29) at 500 nM for 2 hours are indicated in FIGS.29A and 29B, respectively, where internalization of the conjugate isindicated.

All patents, patent applications, provisional applications, andpublications referred to or cited herein are incorporated by referencein their entirety, including all figures and tables, to the extent theyare not inconsistent with the explicit teachings of this specification.

It should be understood that the examples and embodiments describedherein are for illustrative purposes only and that various modificationsor changes in light thereof will be suggested to persons skilled in theart and are to be included within the spirit and purview of thisapplication.

We claim:
 1. An aptamer-N-heterocyclic-carbene metal complex conjugate(aptamer-NHCM conjugate), comprising: an aptamer; at least oneN-heterocyclic-carbene metal complex (NHCM) orbis-N-heterocyclic-carbene metal complex (bis-NHCM): and a couplingunit, wherein the coupling unit comprises a hydrolytically stable. 2.The aptamer-N-heterocyclic-carbene metal complex conjugate of claim 1,wherein the N-heterocyclic-carbene metal complex orbis-N-heterocyclic-carbene metal complex comprises a metal selected fromAu, Ag, Pt, Pd, Ru, Ni, or Cu.
 3. The aptamer-N-heterocyclic-carbenemetal complex conjugate of claim 1, wherein the N-heterocyclic-carbenemetal complex or the bis-N-heterocyclic-carbene metal complex comprisesat least one N-heterocyclic-carbene of the structure:

wherein R-groups are independently H, C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl,C₂-C₁₈ alkynyl, C₆-C₁₄ aryl, C₇-C₁₈ arylalkyl, C₈-C₁₈ arylalkenyl,C₈-C₁₈ arylalkynyl, C₁-C₁₈ alkoxy, C₆-C₁₄ aryloxy, C₇-C₁₈ arylalkyloxy,C₂-C₁₈ alkenyloxy, C₂-C₁₈ alkynyloxy, C₈-C₁₈ arylalkenyloxy, C₈-C₃₀arylalkynyloxy, C₂-C₃₀ alkylester, C₇-C₁₅ arylester, C₈-C₃₀alkylarylester, C₃-C₁₈ alkenylester, C₃-C₁₈ alkynylester, C₃-C₁₈ di- orpoly-ether, C₃-C₁₈ di- or poly-etherester, C₃-C₁₈ di- or poly-ester,C₃-C₁₈ di- or poly-amine, C₄-C₁₈ di- or poly-ene and optionallysubstituted or multiply substituted with any of Cl, Br, I, F, OH, R′₂N,R′SO₂, R′SO, R′S, R′₃Si, R′O, NH₂, C(O)OH, N₃, C≡CH, vicinaldisubstituted with C(O)OC(O), a cyclic conjugated diene, any saltsderived therefrom or any condensation or addition derivative substituenttherefrom, wherein R′ can be C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl, C₂-C₁₈alkynyl, C₆-C₁₄ aryl, C₇-C₁₈ arylalkyl, C₈-C₁₈ arylalkenyl, C₈-C₁₈arylalkynyl, C₁-C₁₈ alkoxy, C₆-C₁₄ aryloxy, C₇-C₁₈ arylalkyloxy, C₂-C₁₈alkenyloxy, C₂-C₁₈ alkynyloxy, C₈-C₁₈ arylalkenyloxy, C₈-C₃₀arylalkynyloxy, C₂-C₃₀ alkylester, C₇-C₁₅ arylester, C₈-C₃₀alkylarylester, C₃-C₁₈ alkenylester, C₃-C₁₈ alkynylester, C₃-C₁₈ di- orpoly-ether, C₃-C₁₈ di- or poly-etherester, C₃-C₁₈ di- or poly-ester,C₃-C₁₈ di- or poly-amine, C₄-C₁₈ di- or poly-ene, wherein at least oneof the R groups comprises the condensation or addition derivativesubstituent comprising the coupling unit forming the stable bond betweenthe N-heterocyclic-carbene metal complex and the aptamer, wherein thecondensation or addition derivative substituent is derived fromcondensation or addition of a —NH₂ and —C(O)OH, —N₃, and —C≡CH; —NH₂ andvicinal disubstituted —C(O)OC(O)—, or homocyclic or heterocyclicconjugated diene and —C≡CH or —HC═CH₂, wherein R and R′ groups arelinear, branched, cyclic, polycyclic or any combination thereof, andwherein the N-heterocyclic-carbene is achiral, a racemic mixture,partially resolved enantiomer, resolved enantiomer, resolveddiastereomers, or a mixture of diastereomers.
 4. Theaptamer-N-heterocyclic-carbene metal complex conjugate of claim 1,wherein the bis-N-heterocyclic-carbene metal complex further comprises aframework that positionally fixes the relative proximity and orientationof the N-heterocyclic carbenes of the bis-N-heterocyclic-carbene metalcomplex.
 5. The aptamer-N-heterocyclic-carbene metal complex conjugateof claim 4, wherein the framework and N-heterocyclic carbenes comprise atrans-9,10-dihydro-9,10-ethanoanthracene-11,12-di-oligomethylene-N-heterocyclic-carbene:

where NHC is an N-heterocyclic carbene, wherein the N-heterocycliccarbenes are independently selected from:

wherein n is 1 to 4, R-groups are independently H, C₁-C₁₈ alkyl, C₂-C₁₈alkenyl, C₂-C₁₈ alkynyl, C₆-C₁₄ aryl, C₇-C₁₈ arylalkyl, C₈-C₁₈arylalkenyl, C₈-C₁₈ arylalkynyl, C₁-C₁₈ alkoxy, C₆-C₁₄ aryloxy, C₇-C₁₈arylalkyloxy, C₂-C₁₈ alkenyloxy, C₂-C₁₈ alkynyloxy, C₈-C₁₈arylalkenyloxy, C₈-C₃₀ arylalkynyloxy, C₂-C₃₀ alkylester, C₇-C₁₅arylester, C₈-C₃₀ alkylarylester, C₃-C₁₈ alkenylester, C₃-C₁₈alkynylester, C₃-C₁₈ di- or poly-ether, C₃-C₁₈ di- or poly-etherester,C₃-C₁₈ di- or poly-ester, C₃-C₁₈ di- or poly-amine, C₄-C₁₈ di- orpoly-ene and optionally substituted or multiply substituted with any ofCl, Br, I, F, OH, R′₂N, R′SO₂, R′SO, R′S, R′₃Si, R′O, NH₂, C(O)OH, N₃,C≡CH, vicinal disubstituted with C(O)OC(O), a cyclic conjugated diene,any salts derived therefrom or any condensation or addition derivativesubstituent therefrom, wherein R′ can be C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl,C₂-C₁₈ alkynyl, C₆-C₁₄ aryl, C₇-C₁₈ arylalkyl, C₈-C₁₈ arylalkenyl,C₈-C₁₈ arylalkynyl, C₁-C₁₈ alkoxy, C₆-C₁₄ aryloxy, C₇-C₁₈ arylalkyloxy,C₂-C₁₈ alkenyloxy, C₂-C₁₈ alkynyloxy, C₈-C₁₈ arylalkenyloxy, C₈-C₃₀arylalkynyloxy, C₂-C₃₀ alkylester, C₇-C₁₅ arylester, C₈-C₃₀alkylarylester, C₃-C₁₈ alkenylester, C₃-C₁₈ alkynylester, C₃-C₁₈ di- orpoly-ether, C₃-C₁₈ di- or poly-etherester, C₃-C₁₈ di- or poly-ester,C₃-C₁₈ di- or poly-amine, C₄-C₁₈ di- or poly-ene, wherein one of the Rgroups of the bis-N-heterocyclic-carbene and framework comprises thecondensation or addition derivative substituent comprising the couplingunit forming the stable bond between the N-heterocyclic-carbene metalcomplex and the aptamer, wherein the condensation or addition derivativesubstituent is derived from condensation or addition of a —NH₂ and—C(O)OH, —N₃, and —C≡CH; —NH₂ and vicinal disubstituted —C(O)OC(O)—, orhomocyclic or heterocyclic conjugated diene and —C≡CH or —HC═CH₂,wherein R and R′ groups are linear, branched, cyclic, polycyclic or anycombination thereof, and wherein the N-heterocyclic-carbene is achiral,a racemic mixture, partially resolved enantiomer, resolved enantiomer,resolved diastereomers, or a mixture of diastereomers.
 6. Theaptamer-N-heterocyclic-carbene metal complex conjugate of claim 1,further comprising a fluorescent or phosphorescent dye attached to theat least one N-heterocyclic-carbene metal complex (NHCM) orbis-N-heterocyclic-carbene metal complex (bis-NHCM).
 7. Theaptamer-N-heterocyclic-carbene metal complex conjugate of claim 1,wherein the aptamer-NHCM conjugate is1-(anthracen-9-ylmethyl)-3-(4-N-sgc8c-aptamer-carbamoylbenzyl)benzo[d]imidazoliumgold(I) chloride,1-(methyl)-3-(4-N-sgc8c-aptamer-carbamoylbenzyl)benzo[d]imidazoliumgold(I) chloride,1-(anthracen-9-ylmethyl)-3-(4-N-sgc8c-aptamer-carbamoylbenzyl)benzo[d]imidazolium triphenylphosphino gold(I) tetrafluoroborate, or1-(anthracen-9-ylmethyl)-3-(4-N-AS1411-aptamer-carbamoylbenzyl)benzo[d]imidazolium triphenylphosphino gold(I) tetrafluoroborate
 8. Theaptamer-N-heterocyclic-carbene metal complex conjugate of claim 1,wherein the aptamer binds to a cancer cell specific receptor.
 9. Theaptamer-N-heterocyclic-carbene metal complex conjugate of claim 8,wherein the cancer cell specific receptor is a G-protein coupledreceptor, an epidermal growth factor receptor, an epidermal growthfactor tyrosine kinase receptor mutation variant III, or a proteintyrosine kinase receptor
 7. 10. The aptamer-N-heterocyclic-carbene metalcomplex conjugate of claim 1, wherein the aptamer-N-heterocyclic-carbenemetal complex further comprises at least one bond between a metal of theN-heterocyclic-carbene metal complex and an ion or ligand, wherein theions or ligands independently comprise Cl, Br, I, OH, Cl⁻, Br⁻, I⁻, BF₄⁻, PF₆ ⁻, SbF₆ ⁻, ⁻OSO₂CF₃, or ⁻OSO₂C₆H₅.
 11. Theaptamer-N-heterocyclic-carbene metal complex conjugate of claim 1,wherein a portion of the coupling unit comprises an amide —NHC(O)—, a1,4-substituted triazole —N₃C₂H—; an imide [—C(O)]₂N—, abicycle[2.2.1]heptane —C₇H₈—, a substituted bicycle[2.2.1]heptane, a7-oxabicyclo[2.2.1]heptane —C₆H₆O—, a substituted7-oxabicyclo[2.2.1]heptane, a 7-azabicyclo[2.2.1]heptane —C₆H₇N—, asubstituted 7-azabicyclo[2.2.1]heptane, or a succinimide thioether. 12.The aptamer-N-heterocyclic-carbene metal complex conjugate of claim 1,wherein the aptamer is capable of binding to a specific cell surfacereceptor present on a target cell.
 13. Theaptamer-N-heterocyclic-carbene metal complex conjugate of claim 12,wherein the target cell is a cancer cell and the specific cell surfacereceptor is present on the surface of the cancer cell.
 14. Theaptamer-N-heterocyclic-carbene metal complex conjugate of claim 1,wherein the NHCM is conjugated to the aptamer in a covalent manner. 15.The aptamer-N-heterocyclic-carbene metal complex conjugate of claim 14,wherein the covalent bond between the NHCM and the aptamer is acidlabile.
 16. The aptamer-N-heterocyclic-carbene metal complex conjugateof claim 1, wherein the aptamer is conjugated to the NHCM in anon-covalent manner.
 17. A method of treating a disease, comprisingadministering to a subject in need thereof, a pharmaceutically effectiveamount of the aptamer-N-heterocyclic-carbene metal complex conjugate ofclaim
 1. 18. The method of claim 17, wherein the disease is a cancer ora microbial infection.
 19. The method of claim 18, wherein theaptamer-N-heterocyclic-carbene metal complex conjugate binds to thedisease causing cells via the specific cell surface receptor present onthe disease causing cells.
 20. The method of claim 17, wherein thesubject is a mammal selected from the group consisting of a human, aporcine, a canine, a rodent, a feline, and a bovine.